Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind. , Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik , MD, as Chief Medical... Read More

WARSAW, Ind. , Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025. The cash dividend of $0.24 per share is payable on or about October 31, 2025 to stockholders of record as of the close of business on September 30, 2025... Read More

WARSAW, Ind. , Aug. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Annual Morgan Stanley Healthcare Conference on Monday, September 8, 2025 , at 8:30 a.m. ET . A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . The webcast... Read More

Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency 1 basis and 2.8% on an organic constant currency 1 basis Second quarter diluted earnings per share were $0.77 ; adjusted 1 diluted earnings per share were $2.07 , an increase of 3.0% Company tightens full-year 2025 reported, constant currency 1 and organic constant currency 1 revenue growth guidance to 6.7% - 7.7%, 6.2%... Read More

Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas , July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global... Read More

WARSAW, Ind. , July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET . A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET . The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at... Read More

WARSAW, Ind. , May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025. The cash dividend of $0.24 per share is payable on or about July 31, 2025 to stockholders of record as of the close of business on June 26, 2025 . About... Read More

WARSAW, Ind. , May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos , Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and... Read More

WARSAW, Ind. , May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 , at 9:20 a.m. ET . A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . The... Read More

First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency 1 basis First quarter diluted earnings per share were $0.91 ; adjusted 1 diluted earnings per share were $1.81 Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted 1 earnings per share guidance to include Paragon 28, currency and the impact... Read More

Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind. , April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space.... Read More

WARSAW, Ind. , April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025 , at 8:30 a.m. ET . A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET . The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at... Read More

Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system. The RibFix Advantage Fixation System is intended for the thoracoscopic fixation,... Read More

Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona ® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions WARSAW, Ind. , March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio... Read More

A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind. , March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona ® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals.... Read More

WARSAW, Ind. , March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos , Ms. Cardillo will join the Company on March... Read More

WARSAW, Ind. , Feb. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 27 th Annual Barclays Healthcare Conference on Thursday, March 13, 2025 , at 9:30 a.m. ET . A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . The webcast... Read More

WARSAW, Ind. , Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of... Read More

Schwarzenegger Invites People Living with Joint Pain to Join New Online Community, Share Their Stories and Connect with a Qualified Physician WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the launch of the You'll Be Back campaign with the Company's Chief Movement Officer, Arnold Schwarzenegger . The goal of the You'll Be Back... Read More

WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2025. The cash dividend of $0.24 per share is payable on or about April 30, 2025 to stockholders of record as of the close of business on March 31, 2025.... Read More

WARSAW, Ind. , Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including: Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025 , pursuant to the mandatory director retirement age in... Read More

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency 1 basis Fourth quarter diluted earnings per share were $1.20 ; adjusted 1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency 1 basis Full-year diluted earnings per share were $4.43 ; adjusted 1 diluted earnings per share were $8.00 Company provides full-year 2025... Read More

Demonstrates Zimmer Biomet's Commitment to Investing in Higher Growth End-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet's Financial Profile; Immediately Accretive to Revenue Growth and Accretive to Adjusted EPS within 24 Months of Deal Close WARSAW, Ind. and ENGLEWOOD, Colo. , Jan. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical... Read More

WARSAW, Ind. , Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET . A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET . The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at... Read More

WARSAW, Ind. , Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ( NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 , at 8:15 a.m. PT ( 11:15 a.m. ET ). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at... Read More

WARSAW, Ind. , Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc . (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30,... Read More

New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind. , Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral... Read More

A Total Knee Replacement Alternative for Patients with Metal and/or Bone Cement Sensitivities WARSAW, Ind. , Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona ® SoluTion™ Porous Plasma Spray (PPS ® ) Femur, a total knee implant component offering an alternative for patients with... Read More

WARSAW, Ind. , Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford ® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for... Read More

WARSAW, Ind. , Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024 , with a fireside chat at 8:45 a.m. ET . A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . The webcast... Read More

WARSAW, Ind., and ZURICH , Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing... Read More

Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind. , Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger , who will take on the newly established role... Read More

WARSAW, Ind. , Nov. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Jefferies London Healthcare Conference on November 19, 2024 , with a fireside chat at 11:00 a.m. GMT ( 6:00 a.m. ET ). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at... Read More

Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency 1 basis Third quarter diluted earnings per share were $1.23 ; adjusted 1 diluted earnings per share were $1.74 Company updates 2024 financial guidance, reducing and narrowing range for full year outlook WARSAW, Ind. , Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the... Read More

Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI ® and HAMMR™ Automated Hip Impaction System WARSAW, Ind. , Oct. 28, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the Z1™ Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual... Read More

DURHAM, N.C. and WARSAW, Ind. , June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will... Read More

WARSAW, Ind. , Dec. 14, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of its Executive Management Team are scheduled to present at the Goldman Sachs CEOs Unscripted Conference on Thursday, January 5, 2023 , at 11:25 a.m. ET and at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 , at 3:45 p.m. PT / 6:45... Read More